



# Health Research Authority

## National Research Ethics Service

### NRES Committee North West - Lancaster

Barlow House  
3rd Floor  
4 Minshull Street  
Manchester  
M1 3DZ

Telephone: 0161 625 7818  
Fax: 0161 625 7299

22 May 2014

Ms Sarah E Seaton  
Department of Health Sciences  
22-28 Princess Road West  
Leicester  
LE1 6TP

Dear Ms Seaton

**Study title:** **Modelling neonatal care pathways: costs and consequences for the future**  
**REC reference:** **14/NW/0349**  
**Protocol number:** **0415**  
**IRAS project ID:** **148248**

The Proportionate Review Sub-committee of the NRES Committee North West - Lancaster reviewed the above application on 22 May 2014.

We plan to publish your research summary wording for the above study on the NRES website, together with your contact details, unless you expressly withhold permission to do so. Publication will be no earlier than three months from the date of this favourable opinion letter. Should you wish to provide a substitute contact point, require further information, or wish to make a request to postpone publication, please contact the REC Manager Mrs Carol Ebenezer, [nrescommittee.northwest-lancaster@nhs.net](mailto:nrescommittee.northwest-lancaster@nhs.net).

#### **Ethical opinion**

On behalf of the Committee, the sub-committee gave a favourable ethical opinion of the above research on the basis described in the application form, protocol and supporting documentation, subject to the conditions specified below.

#### **Conditions of the favourable opinion**

The favourable opinion is subject to the following conditions being met prior to the start of the study.

**You should notify the REC in writing once all conditions have been met (except for site approvals from host organisations) and provide copies of any revised documentation with updated version numbers. The REC will acknowledge receipt and provide a final list of the approved documentation for the study, which can be made available to host organisations to facilitate their permission for the study. Failure to provide the final versions to the REC may cause delay in obtaining permissions.**

Management permission or approval must be obtained from each host organisation prior to the start of the study at the site concerned.

*Management permission (“R&D approval”) should be sought from all NHS organisations involved in the study in accordance with NHS research governance arrangements.*

*Guidance on applying for NHS permission for research is available in the Integrated Research Application System or at <http://www.rforum.nhs.uk>.*

*Where a NHS organisation’s role in the study is limited to identifying and referring potential participants to research sites (“participant identification centre”), guidance should be sought from the R&D office on the information it requires to give permission for this activity.*

*For non-NHS sites, site management permission should be obtained in accordance with the procedures of the relevant host organisation.*

*Sponsors are not required to notify the Committee of approvals from host organisations.*

### Registration of Clinical Trials

All clinical trials (defined as the first four categories on the IRAS filter page) must be registered on a publically accessible database within 6 weeks of recruitment of the first participant (for medical device studies, within the timeline determined by the current registration and publication trees).

There is no requirement to separately notify the REC but you should do so at the earliest opportunity e.g. when submitting an amendment. We will audit the registration details as part of the annual progress reporting process.

To ensure transparency in research, we strongly recommend that all research is registered but for non-clinical trials this is not currently mandatory.

If a sponsor wishes to contest the need for registration they should contact Catherine Blewett ([catherineblewett@nhs.net](mailto:catherineblewett@nhs.net)), the HRA does not, however, expect exceptions to be made. Guidance on where to register is provided within IRAS.

**It is the responsibility of the sponsor to ensure that all the conditions are complied with before the start of the study or its initiation at a particular site (as applicable).**

### **Ethical review of research sites**

The favourable opinion applies to all NHS sites taking part in the study, subject to management permission being obtained from the NHS/HSC R&D office prior to the start of the study (see “Conditions of the favourable opinion”).

### **Approved documents**

The documents reviewed and approved were:

Document	Version	Date
Evidence of Sponsor insurance or indemnity (non NHS Sponsors only)		23 April 2014
Letters of invitation to participant	1.3	10 April 2014
Other [Study information leaflet]	7	24 April 2014
REC Application Form	3.5	12 May 2014
Research protocol or project proposal	1.4	10 April 2014

Summary CV for Chief Investigator (CI)	Manktelow	
Summary CV for Chief Investigator (CI)	Seaton	12 May 2014
Summary CV for Chief Investigator (CI)	Abrams	
Summary CV for Chief Investigator (CI)	Draper	

### **Membership of the Proportionate Review Sub-Committee**

The members of the Sub-Committee who took part in the review are listed on the attached sheet.

### **Statement of compliance**

The Committee is constituted in accordance with the Governance Arrangements for Research Ethics Committees and complies fully with the Standard Operating Procedures for Research Ethics Committees in the UK.

### **After ethical review**

#### Reporting requirements

The attached document "After ethical review – guidance for researchers" gives detailed guidance on reporting requirements for studies with a favourable opinion, including:

- Notifying substantial amendments
- Adding new sites and investigators
- Notification of serious breaches of the protocol
- Progress and safety reports
- Notifying the end of the study

The HRA website also provides guidance on these topics, which is updated in the light of changes in reporting requirements or procedures.

#### Feedback

You are invited to give your view of the service that you have received from the National Research Ethics Service and the application procedure. If you wish to make your views known please use the feedback form available on the HRA website <http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance/>

We are pleased to welcome researchers and R & D staff at our NRES committee members' training days – see details at <http://www.hra.nhs.uk/hra-training/>

With the Committee's best wishes for the success of this project.

**14/NW/0349**

**Please quote this number on all correspondence**

Yours sincerely



**Dr Lisa Booth**  
**Chair**

Email: nrescommittee.northwest-lancaster@nhs.net

*Enclosures:* *List of names and professions of members who took part in the review*  
*"After ethical review – guidance for researchers"*

*Copy to:* *Mrs Wendy Gamble,*

**NRES Committee North West - Lancaster****Attendance at PRS Sub-Committee of the REC meeting on 22 May 2014****Committee Members:**

Name	Profession	Present	Notes
Dr Lisa Booth	Senior Lecturer / Chair	Yes	
Mrs Valerie Skinner	Nurse (Retired)	Yes	
Professor Jois Stansfield	Professor of Speech Pathology	Yes	

**Also in attendance:**

Name	Position (or reason for attending)
Mrs Carol Ebenezer	REC Manager